Showing posts with label pharmaceutical companies pricing abuses. Show all posts
Showing posts with label pharmaceutical companies pricing abuses. Show all posts

Wednesday, June 24, 2009

Importation bill has chance to offer example of concern for ALL U.S. citizens, leadership, innovation

The news hit with the suddenness of a surprise attack early Saturday, June 20—the Pharmaceutical industry had made a late night call to Senator Max Baucus (D-MT) to tell him that is was willing to cooperate by pledging $80 billion over the next decade in resolving one of the biggest problems (and resulting criticisms) of Medicare Part D, The Infamous Doughnut Hole.

The facts surfaced by Monday afternoon however, as it became evident that pharma’s move really was nothing more than a carefully crafted and possibly successful attempt to circumvent several challenges facing it—the possibility of price negotiation for Part D medicines, and the potential contribution that could be provided by allowing personal importation of safe, affordable medicines from licensed, registered pharmacies in Tier One designated countries.
The Doughnut Hole should have been called ‘The Black Hole.’ Seniors were forced to continue paying their premiums, but their coverage was ‘suspended’ when drug costs reached $2250. They had entered The Doughnut Hole, where they would pay 100 percent of their prescriptions for the next $3600—even though they still had to pay for their premiums (a windfall for insurance companies). After paying the $3600, the ‘catastrophic’ level was reached, and the seniors who had survived The Doughnut Hole, were eligible for renewed coverage with low cost co-pays.

The fiscal and medical hit upon the elderly was immediate. Many seniors simply quit taking their medicines or began ‘splitting’ pills. Either action not only derailed the claimed hoped-for goals of Medicare Part D, it caused untold numbers of elderly to gamble their health, well-being and perhaps even their lives by the self-denial of vital medicines that had been forced on them by a pharmaceutical-influenced Congress that enacted Part D. Billy Tauzin, the former Congressman from New Orleans who was instrumental for many of the 11th hour (and 59 minute) changes that shaped Part D was rewarded with a multi-million-dollar position by PhRMA, the influential and well-heeled trade group for the drug companies.

A proposed solution to relieving the burden of The Doughnut Hole dilemma—price negotiation for drugs-- soon became a favorite of politicians, and repeated calls were made from untold numbers of stumps, town hall meetings, and locales where the pols could promise the elderly that help was on the way.

With the election of President Barack Obama, a Democratic House and a Democratic Senate, negotiation seemed ready to be moved from stump speeches to reality.

But, it is said that politics makes strange bedfellows. And, the push for healthcare reform soon created a lot of odd sleeping arrangements. Many of us winced when PhRMA joined with FamiliesUSA, a leading progressive, hard-working and well-respected advocacy group, to work for ‘healthcare reform.’ What, we asked, was the industry looking for? Images of the Fox in the Henhouse, the camel with his nose under the tent, flashed though our minds.

Added to this was the White House meeting President Obama arranged with industry groups representing insurance companies, PhRMA, hospitals, and other healthcare industry groups. Our concerns were quickly validated when a White House statement about pledges to cut the growth of health care costs was actually nothing more than a pledge to reduce the rate of growth by not increasing prices as much as before. The President needs to remember what John Kennedy said about big business special interest groups and what a bunch of SOBs they were.

The fact is that the ‘pledge’ was actually not a true savings. It would be a bit like buying your groceries at a store that has raised its prices 20 percent for the past few years. But, to ‘save money’, it says it will raise its prices only 10 percent next year, so instead of groceries that cost $100 per week in year one, the next year they would cost $110 instead of $120. The store owner could then tell consumers that each had saved $10 in year two, even though they were paying more for the same groceries. Only the rate of the increase was less than in previous years.

This type of math should have been the tip-off that the pharma ‘commitment’ to aiding seniors in The Doughnut Hole isn’t what it at first seemed to be.

On Sunday, President Obama issued the following statement about the agreement with the drug companies:

"I am pleased to announce that an agreement has been reached between Senator Max Baucus and the nation’s pharmaceutical companies that will bring down health care costs and reduce the price of prescription drugs for millions of America’s seniors. As part of the health reform legislation that I expect Congress to enact this year, pharmaceutical companies will extend discounts on prescription drugs to millions of seniors who currently are subjected to crushing out-of-pocket expenses when the yearly amounts they pay for medication fall within the doughnut hole any payments by seniors not covered by Medicare that fall between $2700 and $6153.75 per year. The existence of this gap in coverage has been a continuing injustice that has placed a great burden on many seniors. This deal will provide significant relief from that burden for millions of American seniors.

"The agreement by pharmaceutical companies to contribute to the health reform effort comes on the heels of the landmark pledge many health industry leaders made to me last month, when they offered to do their part to reduce health spending $2 trillion over the next decade. We are at a turning point in America’s journey toward health care reform. Key sectors of the health care industry acknowledge what American families and businesses already know - that the status quo is no longer sustainable. The agreement reached today to lower prescription drug costs for seniors will be an important part of the legislation I expect to sign into law in October. I want to commend House chairmen Henry Waxman, George Miller and Charles Rangel for addressing this issue in the health reform legislation they unveiled this week. This is a tangible example of the type of reform that will lower costs while assuring quality health care for every American."

It was to be Monday before the facts began to surface. Simply put, PhRMA had negotiated an arrangement that would become law only if Congress enacted comprehensive healthcare reform, a part of which would include expanded coverage for more Americans, creating new, additional and profitable markets for the pharmaceutical industry. It is distressing to once again witness the ability of pharma to define issues to its advantage. Perhaps I need a refresher course in civics, but why does the industry have to ‘agree’ to cuts that are intended to be a part of the governing legislation enacted by the U.S. Congress? What option do they have?

Also, why is the Obama Administration so ready to heap praises upon the drug companies, all of which have reaped whirlwind, virtually ensured profits at the expense of the American public that has been denied access to the health benefits provided by access to vital medicines because it must pay the highest cost in the world for its prescription medicines?

But, it is an ill-wind that blows no good. Last Fall, before the elections, a group of advocates for senior advocacy groups from areas across the country, met in Washington, DC to shape support for personal importation of prescription medicines from Tier One countries. At that time, the participants reached a consensus that the importation concept should be included as a part of discussion about comprehensive healthcare reform, a ‘third-leg’ of the stool, because such access to vital medicines is essential to the health and well-being of Americans. It also urged consideration of the beneficial budgetary impact that could be provided though the inclusion of personal importation of prescription medicines into Part D thereby remedying plan shortcomings while saving money for the elderly, protecting their health and creating real savings for the Plan.

Sources tell us that moves have made recently by supporters of importation to define a stronger argument for importation of prescription medicines within the framework of the healthcare debate. We applaud such action. Now, there is an additional opportunity to address the benefits of improved health and savings by fine-tuning the healthcare debate to explore other opportunities for personal importation and defining a role for personal importation in Medicare Part D. Senators Dorgan and Snowe, the two legislators most identified with importation, have issued a statement that reflects their realization that the pharma 'offer' really does not address the challenge of lowering prescription drug prices. And, already, there is a growing realization that the pharmaceutical industry's motives are self-serving.

It is time to call out the pharmaceutical industry. There are legitimate questions that deserve answers about the motives of pharma. It has reaped the benefits of guaranteed pricing for Part D that has led to windfall profits. The claimed or hoped-for savings,while beneficial to individuals, is too little-too late for many elderly. As to the claimed savings to be scored by the Congressional Budget Office, there is a growing realization that possible trade-offs to gain pharma support might actually lead to increased--and virtually guaranteed--sales and earnings.

There is a role for personal importation in helping provide a solution to providing safe, affordable prescription medicines for all Americans. We believe the pharma moves should lead to increased discussion of creating such access, free of what we believe to be unnecessary delays by empowering Secretary Sebelius to designate Tier One countries whose standards of oversight, safety, and efficacy meet of exceed those of the U.S.

Tuesday, June 2, 2009

Dorgan-Snowe needs changes

Sometime ago, we published a blog suggesting that problems that we perceived with the proposed prescription medicine importation bill, based on our understanding of input from key staff and communications with other supporters of the concept of the prescription medicine importation led us to fear that key elements of the concept that have long been supported by groups and advocates might somehow not be included in the new legislation.

It was that concern that prompted us to call for increased public participation in the development of the language. Irrespective of what the outcome might have been for our appeal, we believe that such involvement is not only a right given to U.S. citizens, but an obligation for those whom we elect to serve and govern--not rule.

Our specific concerns were that we and others have long believed that it is the right of U.S. citizens to make purchases from Tier One countries, where the regulations, oversight and supervision of pharmacies meet or exceed those of the United States.

We were challenged on this by a visitor to the article who wanted our source to validate the statement. She speculated that it was likely a political reference and tht the FDA had not reached such a conclusion. Of course, she was right on the latter aspect, since the FDA would never face the wrath of pharma by stating the obvious. In the former instance, though, she was just wrong. The fact is that each of the Tier One countries have outstanding regulatory oversight, and it is well-recogized by healthcare professionals and authorities around the world that not only do those countries have standards that meet those of the U.S. and the FDA, but that we as a country are unforunately far behind the standards of those countries.

Which leads to our former concerns about the proposed importation legislation that was was introduced on March 4. We feared that the ability of U.S. citizens to purchase physician-prescribed medicines from Tier One countries was to be limited, and would allow the purchase of medicines from those countries only if they were first purchased by a U.S. importer (a pharmacy, group of pharmacies, or a wholesaler) for resale to Americans.

This seemed to be an unnecessary restriction that would only add to the costs, while doing nothing for safety or efficacy of the medicines.

Unfortunately, the latest 'wrap' explanation of the bill seems to reinforce this view.

After much discussion, and readings of the bill regarding the limitation on individual purchases we came to the mistaken conclusion that the Secretary of HHS would be able to 'designate' particular countries as having standards of oversight and regulation that met or exceeded those of the U.S. and that individuals would be allowed to make purchases from those countries.

The latest explanation of the proposed language has disabused us of our mistake. To the contrary of what we believed, it reinforces our earlier fears and limits direct purchase to mail-order or Internet pharmacies located only in Canada.

This would take effect 90 days after the passage and signing of any importation bill. At the same time, it would be a year before the 'commercial' setup that would allow American citizens to purchase those same medicines from designated countries, and then only from a wholesaler or a U.S. pharmacy.

As one who has supported the concept of importation of medicines from legal, authorized, licensed pharmacies for nearly six years, it is difficult to express my dismay at this short-sighted approach to increasing the access of Americans to safe, affordable prescription medicines--especially at a time when growing numbers of elderly are either reducing or doing without vital medicines because of the problems associated with the Doughnut Hole. And that is only the tip of the iceberg.

Millions of Americans irrespective of their age simply cannot afford their medicines, so they too do without. Ironically, this occurs at a time when there is a solution--expand the ability of Americans to have increased access to safe, affordable medicines, exercising their own good judgment by utilizing the many sources that identify legitimate, safe pharmacies in Tier One countries.

As a writer from the American Enterprise Institute (no friend of importation) noted recently, "Only an idiot would purchase 'medicine' from a bogus pharmacy" because there are many sources than can identify legitimate pharmacies.

The legislation has been referred to the Senate Health, Education, Labor and Pensions Committee and to the House Energy and Commerce committee. Hopefully, there will be hearings at which public testimony will be solicited--and listened to--as part of the democratic process.

I have been told that I am covering old ground. Perhaps that is true. But the facts are evident: importation from licensed, registered pharmacies is a fact and even with (or perhaps because of Part D), it offers a reasoned solution to allowing Americans to have access to vital medicines; to the best of my knowledge, there have been no deaths from any medicines from these pharmacies; no controlled substances have been shipped to this country from these pharmacies.

And,whereas there was no track record when the push for importation first began, and it would have been necessary to establish safeguards to protect and reassure the American public, there is no guarantee that even with passage of the legislation in its current form that it will end or even curtail bogus pharmacies, sales of controlled substances or sales of counterfeit drugs.

The concept of importation, free choice and equitable pricing, with the goal of improved health that can be attained through a regimen of access to safe, affordable medicines remains valid. The challenge now: to establish the framework that will make it happen.

Wednesday, July 23, 2008

Patients buying fewer Prescription Drugs

Posted by Daniel Hines,
Publisher, www.TodaysSeniorsNetwork.com

Proof of the failure of Medicare Part D and the growing number of all Americans not having access to the health benefits of prescription medicines has come forth in a Wall Street Journal story describing how more and more U.S. citizens are unable to afford prescription medicines.

While it is still too early to measure what the harmful effects of this upon Americans' health might be, it is only logical that many people will suffer poorer health. This should end once and for all the approach by many groups and organizations who attempt to divide debate and discussion about comprehensive health care reform into segments based upon the "pet issue" or that particular groups, organizations or policy-makers.

Such an approach virtually guarantees that without including defining how to make safe, affordable prescription medicines more widely available into discussions about healthcare, we are risking the health and well-being of a growing number of Americans. The growth in costs, the decline in consumption and the potential health effects make it imperative that true competition be introduced into the U.S. pharmaceutical market by allowing U.S citizens to exercise their freedom of choice and purchase safe, affordable medicines from identifiable legitimate pharmacies outside the U.S.

Consider: The growth in prescriptions filled by U.S. pharmacies is at its slowest in at least ten years, as increasing health care costs and a slowing economy are making medication harder to afford.

According to the Wall Street Journal article, the drug industry usually remains stable in economic downturns, because patients still require medicine.
However, the number of prescriptions filled in the second quarter of 2008 may have actually decreased, due to higher numbers of Americans without health insurance and “skyrocketing out-of-pocket drug costs” putting the cost of some medications out of reach.

Patients are facing additional burdens as the health care industry has forced consumers to shoulder larger percentages of many costs.
A Kaiser Family Foundation study found that for a “preferred drug” through a tiered insurance plan, average co-payments rose 67 percent from $15 in 2000 to $25 in 2007.

In fact, 23 percent of respondents to a Kaiser foundation poll failed to fill a prescription in the last year for cost reasons, up from 20 percent in 2005.
Additionally, 19 percent either skipped doses or split pills, an increase from 16 percent in 2005.

Prescription Meds from outside U.S. offer lifeline to Part D

Posted by Daniel Hines
Publisher, www.TodaysSeniorsNetwork.com

(Part One of how and why safe, affordable prescription medicines from licensed, registered phamacies from outside the U.S. can benefit not only American's health, but can relieve the strained budgets of governmental services at the local, state and Federal levels. Part Two will deal with how local governments can generate vast savings for employee benefits, savings that can then be applied to other local services.)

As the U.S. economy continues to reel, the increasing cost of Medicare Part D threatens the very essence of a program that was claimed to be designed to address the prescription medicine needs of the country's aging population.

Increasingly, abuses of the system are apparent. Most recently, the Center for Medicare Services says that private plans that are woven in the fiber of Part D, have 'misinterpreted' the intent of CMS when the Part D was launched by developing a practice of 'locking in' a price structure in which PBMs charge a higher rate to insurers with whom they have contracted to administer their drug benefit than what they pay pharmacies to dispense the drugs to beneficiaries. The PBMs then keep the difference, according to an article in the Wall Street Journal.

Ironically, a CMS administrator says that the agency thought it had a "clear policy"
prohibiting lock-in pricing when Part D launched. "We learned that there are different ways of interpreting a policy statement," she adds in a classic understatment.

Actually, since its inception, Medicare Part D has been flawed. It did not allow price negotiation to guarantee the lowest prices thereby generating savings for the Federal government and the intended beneficaries. The abomination of the 'Doughnut Hole' virtually eliminated hundreds of thousands of seniors who would receive little or no benefit unless they had staggering out-of-pocket costs which increase each year. And, the pharmaceutical industry continues to raise prices on brand name drugs, which makes Part D increasingly costly, although a "PR Spin" has been attempted to make it look as though savings have occured since the amount expended is lower than earlier estimates. The fact is that a large part of this claimed savings is due to lower than anticipated enrollment in plans.

In what can only be described as an American Tragedy, many policy-makers attack the claimed original intent of Part D, to help seniors enjoy the health benefits provided by prescription medicines, by labeling Part D (and Social Security and Medicare generally) as 'entitlement' programs that are burdensome to the country. One author even suggests that there is no alternative other than to cut Part D to 'save Medicare':
"In sum, Part D costs are soaring, and they could harm Medicare's core mission and the elderly. Because a tax increase is out of the question, one obvious solution is to amend the law and limit the drug benefit to save Medicare..." Quote from Spyros Andreopoulos is director emeritus of the Office of Communication and Public Affairs at Stanford University Medical Center.

Another approach comes from The Medicare Rights Center, on whose Citizens' Advisory Board I serve (Midwest Region). MRC advocates support of the Medicare Prescription Drug Savings and Choice Act, introduced by U.S. Senator Dick Durbin (D-IL) along with U.S. Representatives Jan Schakowsky (IL-09) and Marion Berry (AR-01). The bill creates a Medicare administered prescription drug plan to provide seniors an alternative to the privately administered prescription drug plans currently offered under Part D.

The problem is that both of the above approaches suffer from the blinders that too often are worn by policy-makers and advocacy groups, blinders that prevent them from looking at the totality of the factors that can favorably influence a solution to challenges such as the increasing costs of Medicare plans.

The fact is that access to safe, affordable prescription medicines from outside the U.S. must be included in the discussion to the complete (debate) (discussion)on healthcare reform in this country. Such access not only offers a potential benefit to improved health for all Americans, but can almost instantly create savings that will favorably impact Medicare administration by allowing access to lower-cost, but safe medications.

Unfortunately, a Washington-based staff member of MRC says that she is interested only in the passage of the Medicare Prescription Drug Savings and Choice Act, on initiatives of the MRC, and has no interest in even exploring the potential contribution of providing savings and choice by allowing access to prescription medicines from outside the U.S.

Also, a highly informative source in Washington has told us that he fears that in the next Congress in 2009, there will be such a rush to enact 'comprehensive health care reform' that it will be nothing more than a 'trading bloc' for a number of individual Senators, Congressmen, pharmaceutical industry and insurance company reps, each with their own particular agenda, be it liberal, conservative, or even anti- or pro-pharmaceutical and insurance industry oriented. He said he fears that pharma particularly will offer its support for some form of 'comprehensive health care reform' in return for the role of providing continued access to safe, affordable medicines from outside this country to U.S. citizens being discarded.

That's like throwing the baby out with the washwater. It is time for Congress to take action to provide such access to all Americans, and to do so in a fashion in which the role of prescription medicines from licensed, registered pharmacies in Tier One countries not only can maintain or even enhance the quality of healthcare in the U.S., but can provide fiscal savings that can actually help pay for other initiatives that will finally get this country on the road to an improved national health care policy.